Additionally, despite TNF-α inhibitors being indicated for psoriasis and UC, the patient’s prior inadequate response to adalimumab, coupled with evidence suggesting that TNF-α therapy may exacerbate psoriatic skin lesions in the context of IBD, renders this treatment option less favorable.[12] Due to contraindications in IBD, IL-17 inhibitors were excluded. The gene discussed is IL17A; the disease is inflammatory bowel disease.